GlassScriptPhysician profile
Marc Todd Silver
NPI 1902802945
$112,536.14
in general payments reported to CMS, 2019-2025
30 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $99.69 · 2021: $32.35 · 2022: $3,955 · 2023: $87K · 2024: $986 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $85K · Food and Beverage: $1,713 · Travel and Lodging: $1,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $85,000.00 |
| Food and Beverage | $1,713.43 |
| Travel and Lodging | $1,296.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daxor Corporation | $90,025.20 | 2022-2023 | Bva-100 |
| Medtronic Vascular, INC. | $20,115.54 | 2019 | |
| Irhythm Technologies, INC. | $370.13 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $287.28 | 2022-2025 | Bodyguardian, Watchman Flx |
| Pfizer INC. | $252.14 | 2019-2025 | |
| Medtronic, INC. | $203.05 | 2021-2025 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $176.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $137.67 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.35 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $98.89 | 2019-2025 | Camzyos, Eliquis |
| Philips North America LLC | $93.15 | 2020-2025 | Extended Holter |
| Heartflow, INC. | $72.10 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $71.92 | 2019-2024 | |
| Abbott Laboratories | $61.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $58.61 | 2023-2024 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $49.61 | 2024-2025 | Nexletol |
| Braemar Manufacturing, LLC | $45.59 | 2019 | |
| Ethicon US, LLC | $40.27 | 2025 | Stratafix, Dermabond, Monocryl |
| Baxter Healthcare | $39.80 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Edwards Lifesciences Corporation | $27.84 | 2019 | |
| Atricure, INC. | $25.53 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Janssen Pharmaceuticals, INC | $24.72 | 2019 | |
| Nuwellis, INC. | $23.26 | 2019 | |
| Davol INC. | $19.60 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.59 | 2025 | Jardiance |
| Amgen INC. | $16.46 | 2023 | Repatha |
| Alnylam Pharmaceuticals INC. | $15.40 | 2025 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $12.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.